PAVmed Inc. (NASDAQ:PAVM) Q4 2022 Earnings Call Transcript

Lishan Aklog: Yes. We’ve had, we have had limited. We did at one point have a fairly extensive inquiries and engage with consultants about European commercialization for EsoGuard. What we discovered is that, that Europe has a pretty robust reimbursement for precision oncology tests. But that the screening side is difficult, that payments for screening tests, I mean, others have, have encountered this Cologuard and others as well, just historically in Europe, don’t there’s just not parody with the U.S. that makes it, that makes sense for us to given, our resource constraints now to seek to launch in Europe. We do have CE Mark, we do have the ability to do so. There are potentially some opportunities in the UK that might be different, but we’re those are relatively just inquiries at this point without a clear plan.

There are other parts of the world that we’ve had inquiries from where we’ve had local diagnostic groups that have asked about doing that. And those are conversations that continue and they may bear fruit and the coming quarters and years. No such conversations with regard to Veris, on the, I think for the international aspect of the Veris business really will have to wait for the implantable device. That some of the service aspects of this and some of the business model, frankly around remote patient monitoring is very different in other parts of the country. So Ed may make the business model more difficult, but once we have the value added smart port functionality, then there’ll be a potential opportunity. And there the playing field in Europe should be relatively level, and we should have some prospects there.

Ed Woo: Great. Well, thank you. And I wish you guys good luck.

Lishan Aklog: Okay. Thanks a lot, Ed.

Operator: And that’s all the time we have for questions. I’d like to turn the call back to Mr. Parks for closing remarks.

Lishan Aklog: I’ll take that operator. So it’s Dr. Aklog. So thank you again everyone, for taking the time and the attention. Thank you for the questions. Really great discussion. We look forward to continuing to update you on our progress, as we always do. For more information please feel free to go to our website the PAVmed website pavmed.com, the lucid website, luciddx.com, and the Veris Health website, which is in under construction. But we look forward to having that up and running soon. As always feel free to contact Mike Parks with any questions. He’s very responsive. His email address is mep@pavmed.com. So thanks again, and everybody have a great day.

Operator: This concludes today’s conference call. Thank you for attending.